NCT04927065: A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants |
|
|
| Completed | 2/3 | 5404 | US | mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, mRNA-1273.231 | ModernaTX, Inc. | SARS-CoV-2 | 11/23 | 11/23 | | |
| Completed | 2 | 1270 | US | AS03, BNT162b2, BNT162b2 (B.1.1.529), BNT162b2 (B.1.351), BNT162b2 bivalent (wildtype and Omicron BA.1), BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5), CoV2 preS dTM [B.1.351], CoV2 preS dTM/D614, CoV2 preS dTM/D614+B.1.351, mRNA-1273, mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, Sodium Chloride, 0.9% | National Institute of Allergy and Infectious Diseases (NIAID) | COVID-19 | 11/23 | 11/23 | | |
